Q-omics provides the consensus-scored RPL39P25 profile across patient tissues and cancer cell-line models. RPL39P25 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, RPL39P25 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, RPL39P25 RNA expression shows 5,967 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, BRCA, and STAD as cancer lineages where RPL39P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL39P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL39P25 survival associations across molecular data types. RPL39P25 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL39P25 RNA expression–survival associations across cancer types. High RPL39P25 expression shows unfavorable associations in THYM, BRCA, LUSC, TGCT, SKCM and LIHC. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THYM as the clearest survival context for RPL39P25 RNA expression.
This table summarizes RPL39P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL39P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL39P25 shows higher tumor expression in BRCA and KIRC. The BRCA box plot shows higher RPL39P25 RNA expression in tumor versus normal tissue (log2 FC = +0.051, t-test p = .023).
This table shows molecular features associated with RPL39P25 in patient tissues and cancer cell lines. In patient samples, RPL39P25 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
